Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 7241Neoplasms 4538Prostatic Neoplasms 3489Colorectal Neoplasms 2939Carcinoma, Non-Small-Cell Lung 2829Lung Neoplasms 2546Leukemia, Myeloid, Acute 1982Pancreatic Neoplasms 1873Multiple Myeloma 1810Carcinoma, Hepatocellular 1732Neoplasm Metastasis 1585Stomach Neoplasms 1501Lymphoma 1456Precursor Cell Lymphoblastic Leukemia-Lymphoma 1435Head and Neck Neoplasms 1434Brain Neoplasms 1370Melanoma 1346Ovarian Neoplasms 1342Leukemia 1303Rectal Neoplasms 1270Recurrence 1254Colonic Neoplasms 1204Glioblastoma 1137Uterine Cervical Neoplasms 1096Lymphoma, Non-Hodgkin 1065Leukemia, Lymphocytic, Chronic, B-Cell 989Esophageal Neoplasms 965Lymphoma, Follicular 936Lymphoma, Large B-Cell, Diffuse 932Squamous Cell Carcinoma of Head and Neck 921

Interventions

Sugars 1Adrenal Cortex Hormones 14-Aminopyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Interventional × Myelitis × Clear all
NCT07100990 2026-05-05

TIMELY-PLEX

Mayo Clinic

Phase 3 Recruiting
382 enrolled

Myelitis, Myelitis, Transverse, Optic Neuritis

NCT02166346 2018-04-17

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

Johns Hopkins University

Phase 2 Completed
24 enrolled 10 charts

Myelitis, Myelitis, Transverse, Neuromyelitis Optica

Data powered by HemOnc (CC BY 4.0) Colophon âš¡